Sertraline
- Generic Name
- Sertraline
- Brand Names
- Zoloft
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17Cl2N
- CAS Number
- 79617-96-2
- Unique Ingredient Identifier
- QUC7NX6WMB
- Background
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.
- Indication
Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.
- Associated Conditions
- Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
- Associated Therapies
- -
Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury
- Conditions
- Traumatic Brain Injury
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Walter Reed Army Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00208585
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
- Conditions
- Phobia, SocialPanic DisorderAgoraphobiaObsessive-Compulsive DisorderMajor Depressive DisorderAnxiety Disorders
- Interventions
- Drug: PlaceboDrug: Sertraline
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 170
- Registration Number
- NCT00182533
- Locations
- 🇨🇦
MacAnxiety Research Centre, Hamilton, Ontario, Canada
A Study of Sertraline to Prevent PTSD
- Conditions
- Posttraumatic Stress DisorderDepression
- Interventions
- Drug: PlaceboDrug: Sertraline
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT00182078
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes
- Conditions
- DepressionCerebrovascular Accident
- Interventions
- Drug: sertralineDrug: Placebo
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 154
- Registration Number
- NCT00177424
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Dynamic Measures of Neurochemistry in Mood Disorders
- Conditions
- Depression
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT00178828
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Sertraline vs. Venlafaxine XR
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 20
- Registration Number
- NCT00179283
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
- Conditions
- Major DepressionBipolar DisorderUnipolar Depression
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 220
- Registration Number
- NCT00158990
- Locations
- 🇺🇸
Global Medical Institutes, Princeton, New Jersey, United States
🇮🇱Hadassah Medical Organisation, Jerusalem, Israel
Treatments for Psychogenic Nonepileptic Seizures (NES)
- Conditions
- Stress Disorders, Post-TraumaticDepressionConvulsion, Non-EpilepticConversion Disorder
- Interventions
- Drug: placeboDrug: sertraline
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT00159965
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00143091
- Locations
- 🇷🇺
Pfizer Investigational Site, St.-Petersburg, Russian Federation
Comparison of Two Treatments for Post-Traumatic Stress Disorder
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- Behavioral: Cognitive behavioral therapy (CBT)Drug: Sertraline
- First Posted Date
- 2005-08-08
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 200
- Registration Number
- NCT00127673
- Locations
- 🇺🇸
Department of Psychology, University of Washington, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.